Exact Sciences Cor (EXAS) 18.11 $EXAS
Exact Sciences Grants Inducement Restricted Stock Unit Awards to Recently Hired Employees
PR Newswire - Fri Jul 29, 3:02PM CDT
Exact Sciences Corp. (NASDAQ: EXAS) today announced that, in support of the Company's continued growth plans, it granted restricted stock units covering a total of 214,035 shares of common stock to 58 recently hired employees under its previously announced inducement grant program. The restricted stock unit awards vest in four equal annual installments beginning on the first anniversary of the grant date. The awards were approved by the independent Compensation Committee of the Company's Board of Directors and were granted as an inducement material to the recently hired employees entering into employment with the Company in accordance with NASDAQ Marketplace Rule 5635(c)(4). The Company is making this announcement as required by NASDAQ rules.
EXAS: 18.11 (+0.73)
Exact Sciences Announces Upsizing and Pricing of Public Offering of Common Stock
PR Newswire - Thu Jul 28, 7:00AM CDT
Exact Sciences Corporation (NASDAQ: EXAS) today announced the upsizing and pricing of its previously announced underwritten public offering of common stock. The Company is selling 8,500,000 shares of common stock through the underwriters at a public offering price of $15.50 per share. The offering was increased to 8,500,000 shares from the previously announced offering of 7,000,000 shares due to market demand. The Company has also granted the underwriters an option to purchase up to 1,275,000 additional shares. The offering is being underwritten by Jefferies LLC and Robert W. Baird & Co. Incorporated, as joint book-running managers of the offering, and Canaccord Genuity Inc., as co-manager of the offering, and is expected to close on or about August 2, 2016, subject to customary closing conditions.
EXAS: 18.11 (+0.73)
Exact Sciences Announces Agreement to Sell 7,000,000 Common Shares
BusinessWire - Wed Jul 27, 3:01PM CDT
Exact Sciences Corporation (NASDAQ: EXAS) today announced an agreement to sell 7,000,000 shares of its common stock to Jefferies LLC, Robert W. Baird & Co. Incorporated and Canaccord Genuity Inc. as underwriters in an underwritten public offering pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC"
on Form S-3. The Company has also granted the underwriters an option to purchase up to 1,050,000 additional shares.
EXAS: 18.11 (+0.73)
Five Trending Stocks Leading Biotech Sector on Heels of Latest R&D and Innovative Drug Therapy Advancements
PR Newswire Europe - Wed Jul 27, 7:31AM CDT
CORAL SPRINGS, Florida, July 27, 2016 /PRNewswire/ --
KOOL: 4.47 (+0.29), ALIM: 2.08 (+0.03), CBIO: 1.44 (-0.05), EXAS: 18.11 (+0.73)
After Yesterday's Rally of 27.37% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Jul 26, 12:05PM CDT
Exact Sciences (NASDAQ:EXAS) traded in a range yesterday that spanned from a low of $14.57 to a high of $17.47. Yesterday, the shares gained 27.4%, which took the trading range above the 3-day high of $12.75 on volume of 22.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EXAS: 18.11 (+0.73)
Exact Sciences Completes 54,000 Cologuard Tests during the Second Quarter
PR Newswire - Tue Jul 26, 4:00AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenues of $21.2 million during the second quarter ended June 30, 2016, representing a 161-percent increase from $8.1 million in the second quarter of 2015. The company completed approximately 54,000 Cologuard tests during the second quarter, an increase of approximately 160 percent compared to the 21,000 tests completed during the same period of 2015. Since Cologuard's launch and through the end of the second quarter of 2016, approximately 41,000 physicians have ordered the test.
EXAS: 18.11 (+0.73)
Technical Coverage of Medical Laboratories and Research Equities -- Exact Sciences, Alere, DexCom, and VWR Corp.
PR Newswire - Fri Jul 15, 7:30AM CDT
On Thursday, July 14, 2016, the NASDAQ Composite ended the trading session at 5,034.06, up 0.57%; the Dow Jones Industrial Average edged 0.73% higher, to finish at 18,506.41; and the S&P 500 closed at 2,163.75, up 0.53%. The gains were broad based as eight out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Exact Sciences Corporation (NASDAQ: EXAS), Alere Inc. (NYSE: ALR), DexCom Inc. (NASDAQ: DXCM), and VWR Corporation (NASDAQ: VWR). Learn more about these stocks by accessing their free notes at:
DXCM: 92.65 (+0.42), VWR: 31.31 (-0.01), EXAS: 18.11 (+0.73), ALR: 36.97 (-0.53)
92.7% Return Seen to Date on SmarTrend Exact Sciences Call (EXAS)
Comtex SmarTrend(R) - Wed Jul 13, 12:41PM CDT
SmarTrend identified an Uptrend for Exact Sciences (NASDAQ:EXAS) on June 6th, 2016 at $7.13. In approximately 1 month, Exact Sciences has returned 92.68% as of today's recent price of $13.73.
EXAS: 18.11 (+0.73)
Exact Sciences Has Returned 52.1% Since SmarTrend Recommendation (EXAS)
Comtex SmarTrend(R) - Tue Jun 21, 12:17AM CDT
SmarTrend identified an Uptrend for Exact Sciences (NASDAQ:EXAS) on June 6th, 2016 at $7.13. In approximately 2 weeks, Exact Sciences has returned 52.14% as of today's recent price of $10.84.
EXAS: 18.11 (+0.73)
Upgrade Alert for Exact Sciences (EXAS)
Comtex SmarTrend(R) - Fri Jun 17, 3:11AM CDT
Exact Sciences (NASDAQ:EXAS) was upgraded from Hold to Buy at Craig-Hallum today. The stock closed yesterday at $11.25 on volume of 36.6 million shares, above average daily volume of 1.9 million. EXACT Sciences Corporation is an applied genomics company that develops and commercializes proprietary DNA-based tests for the early detection of cancer. The Company's PreGen-Plus is intended for the early detection of colorectal cancer in the average-risk population.
EXAS: 18.11 (+0.73)
Look for Shares of Exact Sciences to Potentially Pullback after Yesterday's 5.54% Rise
Comtex SmarTrend(R) - Wed Jun 15, 11:45AM CDT
Exact Sciences (NASDAQ:EXAS) traded in a range yesterday that spanned from a low of $9.73 to a high of $11.24. Yesterday, the shares gained 5.5%, which took the trading range above the 3-day high of $9.73 on volume of 22.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EXAS: 18.11 (+0.73)
Exact Sciences Appoints Jeff Elliott to Lead Business Development & Strategy
PR Newswire - Fri Jun 03, 5:00AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that Jeff Elliott, a former senior research analyst who covered the diagnostic and lab industries, will join the company as vice president, business development and strategy, effective June 20, 2016. In his new role, Mr. Elliott will oversee the identification and pursuit of strategic business opportunities, while also helping drive Cologuard's continued success.
EXAS: 18.11 (+0.73)
Exact Sciences to participate in three investor conferences during June
PR Newswire - Wed Jun 01, 3:15PM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in three investor conferences during June.
EXAS: 18.11 (+0.73)
Cologuard Available In-Network for Anthem Blue Cross and Blue Shield Members in Five Additional Midwest States
PR Newswire - Wed Jun 01, 5:00AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) announced today that under a recently-signed contract, Exact Sciences is now an in-network provider of Cologuard with Anthem Blue Cross and Blue Shield in the states of Indiana, Ohio, Kentucky, Missouri and Wisconsin.
EXAS: 18.11 (+0.73)
Exact Sciences to participate in two investor conferences during May
PR Newswire - Thu May 05, 5:00AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in two investor conferences during May.
EXAS: 18.11 (+0.73)
Downgrade Alert for Exact Sciences (EXAS)
Comtex SmarTrend(R) - Thu May 05, 3:52AM CDT
Exact Sciences (NASDAQ:EXAS) was downgraded from Buy to Neutral at Mizuho today. The stock closed yesterday at $5.81 on volume of 3.3 million shares, above average daily volume of 1.8 million. Over the past year, Exact Sciences has traded in a range of $4.67 to $32.85 and closed yesterday at $5.81, 24% above that low. The 200-day and 50-day moving averages have moved 2.73% lower and 0.01% higher over the past week, respectively.
EXAS: 18.11 (+0.73)
Buy Exact Sciences Stock After a 72% Price Drop? 3 Things You Need to Know
Rich Smith, The Motley Fool - Motley Fool - Wed May 04, 12:40PM CDT
Shares of early cancer-detector Exact Sciences stock have lost 72% of their value over the past 52 weeks. This week alone, the stock shed 14% in the two days following its Q1 2016 earnings report -- a report that showed Exact Sciences beat...
EXAS: 18.11 (+0.73)
Exact Sciences reports 1Q loss
Automated Insights - Tue May 03, 4:05AM CDT
MADISON, Wis. (AP) _ Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $47.5 million in its first quarter.
EXAS: 18.11 (+0.73)
Exact Sciences Grants Inducement Restricted Stock Unit Awards to Recently Hired Employees
PR Newswire - Fri Jul 29, 3:02PM CDT
Exact Sciences Corp. (NASDAQ: EXAS) today announced that, in support of the Company's continued growth plans, it granted restricted stock units covering a total of 214,035 shares of common stock to 58 recently hired employees under its previously announced inducement grant program. The restricted stock unit awards vest in four equal annual installments beginning on the first anniversary of the grant date. The awards were approved by the independent Compensation Committee of the Company's Board of Directors and were granted as an inducement material to the recently hired employees entering into employment with the Company in accordance with NASDAQ Marketplace Rule 5635(c)(4). The Company is making this announcement as required by NASDAQ rules.
EXAS: 18.11 (+0.73)
Exact Sciences Announces Upsizing and Pricing of Public Offering of Common Stock
PR Newswire - Thu Jul 28, 7:00AM CDT
Exact Sciences Corporation (NASDAQ: EXAS) today announced the upsizing and pricing of its previously announced underwritten public offering of common stock. The Company is selling 8,500,000 shares of common stock through the underwriters at a public offering price of $15.50 per share. The offering was increased to 8,500,000 shares from the previously announced offering of 7,000,000 shares due to market demand. The Company has also granted the underwriters an option to purchase up to 1,275,000 additional shares. The offering is being underwritten by Jefferies LLC and Robert W. Baird & Co. Incorporated, as joint book-running managers of the offering, and Canaccord Genuity Inc., as co-manager of the offering, and is expected to close on or about August 2, 2016, subject to customary closing conditions.
EXAS: 18.11 (+0.73)
Exact Sciences Announces Agreement to Sell 7,000,000 Common Shares
BusinessWire - Wed Jul 27, 3:01PM CDT
Exact Sciences Corporation (NASDAQ: EXAS) today announced an agreement to sell 7,000,000 shares of its common stock to Jefferies LLC, Robert W. Baird & Co. Incorporated and Canaccord Genuity Inc. as underwriters in an underwritten public offering pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC"
on Form S-3. The Company has also granted the underwriters an option to purchase up to 1,050,000 additional shares. EXAS: 18.11 (+0.73)
Five Trending Stocks Leading Biotech Sector on Heels of Latest R&D and Innovative Drug Therapy Advancements
PR Newswire Europe - Wed Jul 27, 7:31AM CDT
CORAL SPRINGS, Florida, July 27, 2016 /PRNewswire/ --
KOOL: 4.47 (+0.29), ALIM: 2.08 (+0.03), CBIO: 1.44 (-0.05), EXAS: 18.11 (+0.73)
After Yesterday's Rally of 27.37% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Jul 26, 12:05PM CDT
Exact Sciences (NASDAQ:EXAS) traded in a range yesterday that spanned from a low of $14.57 to a high of $17.47. Yesterday, the shares gained 27.4%, which took the trading range above the 3-day high of $12.75 on volume of 22.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EXAS: 18.11 (+0.73)
Exact Sciences Completes 54,000 Cologuard Tests during the Second Quarter
PR Newswire - Tue Jul 26, 4:00AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenues of $21.2 million during the second quarter ended June 30, 2016, representing a 161-percent increase from $8.1 million in the second quarter of 2015. The company completed approximately 54,000 Cologuard tests during the second quarter, an increase of approximately 160 percent compared to the 21,000 tests completed during the same period of 2015. Since Cologuard's launch and through the end of the second quarter of 2016, approximately 41,000 physicians have ordered the test.
EXAS: 18.11 (+0.73)
Technical Coverage of Medical Laboratories and Research Equities -- Exact Sciences, Alere, DexCom, and VWR Corp.
PR Newswire - Fri Jul 15, 7:30AM CDT
On Thursday, July 14, 2016, the NASDAQ Composite ended the trading session at 5,034.06, up 0.57%; the Dow Jones Industrial Average edged 0.73% higher, to finish at 18,506.41; and the S&P 500 closed at 2,163.75, up 0.53%. The gains were broad based as eight out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Exact Sciences Corporation (NASDAQ: EXAS), Alere Inc. (NYSE: ALR), DexCom Inc. (NASDAQ: DXCM), and VWR Corporation (NASDAQ: VWR). Learn more about these stocks by accessing their free notes at:
DXCM: 92.65 (+0.42), VWR: 31.31 (-0.01), EXAS: 18.11 (+0.73), ALR: 36.97 (-0.53)
92.7% Return Seen to Date on SmarTrend Exact Sciences Call (EXAS)
Comtex SmarTrend(R) - Wed Jul 13, 12:41PM CDT
SmarTrend identified an Uptrend for Exact Sciences (NASDAQ:EXAS) on June 6th, 2016 at $7.13. In approximately 1 month, Exact Sciences has returned 92.68% as of today's recent price of $13.73.
EXAS: 18.11 (+0.73)
Exact Sciences Has Returned 52.1% Since SmarTrend Recommendation (EXAS)
Comtex SmarTrend(R) - Tue Jun 21, 12:17AM CDT
SmarTrend identified an Uptrend for Exact Sciences (NASDAQ:EXAS) on June 6th, 2016 at $7.13. In approximately 2 weeks, Exact Sciences has returned 52.14% as of today's recent price of $10.84.
EXAS: 18.11 (+0.73)
Upgrade Alert for Exact Sciences (EXAS)
Comtex SmarTrend(R) - Fri Jun 17, 3:11AM CDT
Exact Sciences (NASDAQ:EXAS) was upgraded from Hold to Buy at Craig-Hallum today. The stock closed yesterday at $11.25 on volume of 36.6 million shares, above average daily volume of 1.9 million. EXACT Sciences Corporation is an applied genomics company that develops and commercializes proprietary DNA-based tests for the early detection of cancer. The Company's PreGen-Plus is intended for the early detection of colorectal cancer in the average-risk population.
EXAS: 18.11 (+0.73)
Look for Shares of Exact Sciences to Potentially Pullback after Yesterday's 5.54% Rise
Comtex SmarTrend(R) - Wed Jun 15, 11:45AM CDT
Exact Sciences (NASDAQ:EXAS) traded in a range yesterday that spanned from a low of $9.73 to a high of $11.24. Yesterday, the shares gained 5.5%, which took the trading range above the 3-day high of $9.73 on volume of 22.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EXAS: 18.11 (+0.73)
Exact Sciences Appoints Jeff Elliott to Lead Business Development & Strategy
PR Newswire - Fri Jun 03, 5:00AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that Jeff Elliott, a former senior research analyst who covered the diagnostic and lab industries, will join the company as vice president, business development and strategy, effective June 20, 2016. In his new role, Mr. Elliott will oversee the identification and pursuit of strategic business opportunities, while also helping drive Cologuard's continued success.
EXAS: 18.11 (+0.73)
Exact Sciences to participate in three investor conferences during June
PR Newswire - Wed Jun 01, 3:15PM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in three investor conferences during June.
EXAS: 18.11 (+0.73)
Cologuard Available In-Network for Anthem Blue Cross and Blue Shield Members in Five Additional Midwest States
PR Newswire - Wed Jun 01, 5:00AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) announced today that under a recently-signed contract, Exact Sciences is now an in-network provider of Cologuard with Anthem Blue Cross and Blue Shield in the states of Indiana, Ohio, Kentucky, Missouri and Wisconsin.
EXAS: 18.11 (+0.73)
Exact Sciences to participate in two investor conferences during May
PR Newswire - Thu May 05, 5:00AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in two investor conferences during May.
EXAS: 18.11 (+0.73)
Downgrade Alert for Exact Sciences (EXAS)
Comtex SmarTrend(R) - Thu May 05, 3:52AM CDT
Exact Sciences (NASDAQ:EXAS) was downgraded from Buy to Neutral at Mizuho today. The stock closed yesterday at $5.81 on volume of 3.3 million shares, above average daily volume of 1.8 million. Over the past year, Exact Sciences has traded in a range of $4.67 to $32.85 and closed yesterday at $5.81, 24% above that low. The 200-day and 50-day moving averages have moved 2.73% lower and 0.01% higher over the past week, respectively.
EXAS: 18.11 (+0.73)
Buy Exact Sciences Stock After a 72% Price Drop? 3 Things You Need to Know
Rich Smith, The Motley Fool - Motley Fool - Wed May 04, 12:40PM CDT
Shares of early cancer-detector Exact Sciences stock have lost 72% of their value over the past 52 weeks. This week alone, the stock shed 14% in the two days following its Q1 2016 earnings report -- a report that showed Exact Sciences beat...
EXAS: 18.11 (+0.73)
Exact Sciences reports 1Q loss
Automated Insights - Tue May 03, 4:05AM CDT
MADISON, Wis. (AP) _ Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $47.5 million in its first quarter.
EXAS: 18.11 (+0.73)
